Please sign in to follow a disease.
KCNT1-related epilepsy
Clinical trials for KCNT1-related epilepsy explained in plain language.
Never miss a new study
Get alerted when new KCNT1-related epilepsy trials appear
Sign up with your email to follow new studies for KCNT1-related epilepsy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with rare seizure disorder: drug trial launches
Disease control Recruiting nowThis study tests an experimental drug called ABS-1230 in children and young adults (ages 1 month to under 22 years) with a rare epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can reduce the number of seizures compared to a placebo. Partic…
Matched conditions: KCNT1-RELATED EPILEPSY
Phase 2 • Sponsor: Actio Biosciences, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New epilepsy drug candidate enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial is testing a new drug called ABS-1230 in 74 healthy adults to see if it is safe and how the body processes it. The drug is being developed for a rare type of epilepsy caused by changes in the KCNT1 gene. Participants will receive either the drug or a placeb…
Matched conditions: KCNT1-RELATED EPILEPSY
Phase 1 • Sponsor: Actio Biosciences, Inc. • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC